perindopril arginine actavis 10 mg filmdragerad tablett
actavis group ptc ehf. - perindoprilarginin - filmdragerad tablett - 10 mg - laktosmonohydrat hjälpämne; perindoprilarginin 10 mg aktiv substans
perindopril arginine actavis 2,5 mg filmdragerad tablett
actavis group ptc ehf. - perindoprilarginin - filmdragerad tablett - 2,5 mg - laktosmonohydrat hjälpämne; perindoprilarginin 2,5 mg aktiv substans
perindopril arginine actavis 5 mg filmdragerad tablett
actavis group ptc ehf. - perindoprilarginin - filmdragerad tablett - 5 mg - laktosmonohydrat hjälpämne; perindoprilarginin 5 mg aktiv substans
tektrotyd 20 mikrogram beredningssats för radioaktivt läkemedel
narodowe centrum badan jadrowych - hynic-(d-phe-1-tyr-3-oktreotid)-trifluoroacetat (1:2) - beredningssats för radioaktivt läkemedel - 20 mikrogram - mannitol hjälpämne; hynic-(d-phe-1-tyr-3-oktreotid)-trifluoroacetat (1:2) 50 mikrog aktiv substans
libtayo
regeneron ireland designated activity company (dac) - cemiplimab - carcinom, squamous cell - antineoplastiska medel - cutaneous squamous cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with metastatic or locally advanced cutaneous squamous cell carcinoma (mcscc or lacscc) who are not candidates for curative surgery or curative radiation. basal cell carcinomalibtayo as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic basal cell carcinoma (labcc or mbcc) who have progressed on or are intolerant to a hedgehog pathway inhibitor (hhi). non-small cell lung cancerlibtayo as monotherapy is indicated for the first-line treatment of adult patients with non-small cell lung cancer (nsclc) expressing pd-l1 (in ≥ 50% tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. libtayo in combination with platinum‐based chemotherapy is indicated for the first‐line treatment of adult patients with nsclc expressing pd-l1 (in ≥ 1% of tumour cells), with no egfr, alk or ros1 aberrations, who have:locally advanced nsclc who are not candidates for definitive chemoradiation, ormetastatic nsclc. cervical cancerlibtayo as monotherapy is indicated for the treatment of adult patients with recurrent or metastatic cervical cancer and disease progression on or after platinum-based chemotherapy.
alvesco 160 mikrogram/dos inhalationsspray, lösning
paranova läkemedel ab - ciklesonid - inhalationsspray, lösning - 160 mikrogram/dos - etanol, vattenfri hjälpämne; ciklesonid 0,16 mg aktiv substans - ciklesonid
alvesco 160 mikrogram/dos inhalationsspray, lösning
orifarm ab - ciklesonid - inhalationsspray, lösning - 160 mikrogram/dos - etanol, vattenfri hjälpämne; ciklesonid 0,16 mg aktiv substans - ciklesonid
alvesco 160 mikrogram/dos inhalationsspray, lösning
orifarm ab - ciklesonid - inhalationsspray, lösning - 160 mikrogram/dos - ciklesonid 0,16 mg aktiv substans; etanol, vattenfri hjälpämne - ciklesonid
alvesco 160 mikrogram/dos inhalationsspray, lösning
medartuum ab - ciklesonid - inhalationsspray, lösning - 160 mikrogram/dos - ciklesonid 0,16 mg aktiv substans; etanol, vattenfri hjälpämne
alvesco 160 mikrogram/dos inhalationsspray, lösning
orifarm ab - ciklesonid - inhalationsspray, lösning - 160 mikrogram/dos - ciklesonid 0,16 mg aktiv substans; etanol, vattenfri hjälpämne